The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2024

Filed:

Aug. 04, 2021
Applicant:

Medtronic Minimed, Inc., Northridge, CA (US);

Inventors:

Di Wu, Glendale, CA (US);

Rebecca K. Gottlieb, Culver City, CA (US);

Benyamin Grosman, Winnetka, CA (US);

Anirban Roy, Agoura Hills, CA (US);

Neha J. Parikh, West Hills, CA (US);

Ohad Cohen, Kiryat Uno, IL;

Assignee:

MEDTRONIC MINIMED, INC., Northridge, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M 5/172 (2006.01); A61B 5/145 (2006.01); A61M 5/142 (2006.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/50 (2018.01);
U.S. Cl.
CPC ...
A61M 5/1723 (2013.01); A61B 5/14532 (2013.01); A61M 5/14244 (2013.01); G16H 20/17 (2018.01); G16H 40/63 (2018.01); G16H 50/20 (2018.01); G16H 50/50 (2018.01); A61M 2005/14208 (2013.01); A61M 2205/50 (2013.01); A61M 2205/581 (2013.01); A61M 2205/583 (2013.01);
Abstract

Disclosed herein are techniques related to management of insufficient hypoglycemia response. In some embodiments, the techniques may involve obtaining an amount of insulin remaining in a body of a patient. The techniques may involve also obtaining a quantity of insulin needed by the patient within a future time period. Additionally, the techniques may involve identifying a condition in which the patient's glucose level will continue to decrease during the future time period despite suspension of basal insulin dosage delivery. The condition may be identified based on determining that the amount of insulin remaining in the body is greater than the quantity of insulin needed by the patient within the future time period. Furthermore, the techniques may involve, responsive to identifying the condition, causing performance of an action for preventing the patient's glucose level from falling into a hypoglycemic range in combination with the suspension of basal insulin dosage delivery.


Find Patent Forward Citations

Loading…